Abstract
Introduction Linkage to HIV care remains suboptimal among men. We investigated the effectiveness of a male-targeted HIV-specific decision support app, Empowering People through Informed Choices for HIV (EPIC-HIV), on increasing linkage to HIV care among men in rural South Africa.
Methods Home-Based Intervention to Test and Start (HITS) was a multi-component cluster-randomized controlled trial among 45 communities in uMkhanyakude, KwaZulu-Natal. The development of EPIC-HIV was guided by self-determination theory and human-centered intervention design to increase intrinsic motivation to seek HIV testing and care among men. EPIC-HIV was offered in two stages: EPIC-HIV 1 at the time of home-based HIV counseling and testing (HBHCT), and EPIC-HIV 2 at 1 month after positive HIV diagnosis. Sixteen communities were randomly assigned to the arms to receive EPIC-HIV, and 29 communities to the arms without EPIC-HIV. Among all eligible men, we compared linkage to care (initiation or resumption of antiretroviral therapy after >3 months of care interruption) at local clinics within 1 year of a home visit, which was ascertained from individual clinical records. Intention-to-treat analysis was performed using modified Poisson regression with adjustment for receiving another intervention (i.e., financial incentives) and clustering at the community level. We also conducted a satisfaction survey for EPIC-HIV 2.
Results Among all 13,894 eligible men (i.e., ≥15 years and resident in the 45 communities), 20.7% received HBHCT, resulting in 122 HIV-positive tests. Among these, 54 men linked to care within 1 year after HBHCT. Additionally, of the 13,765 eligible participants who did not receive HBHCT or received HIV-negative results, 301 men linked to care within 1 year. Overall, only 13 men received EPIC-HIV 2. The proportion of linkage to care did not differ in the arms assigned to EPIC-HIV compared to those without EPIC-HIV (adjusted risk ratio=1.05; 95% CI:0.86-1.29). All 13 men who used EPIC-HIV 2 reported the app was acceptable, user-friendly, and useful for getting information on HIV testing and treatment.
Conclusion Reach was low although acceptability and usability of the app was very high among those who engaged with it. Enhanced digital support applications could form part of interventions to increase knowledge of HIV treatment for men.
Clinical Trial Number: ClinicalTrials.gov # NCT03757104
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov # NCT03757104
Funding Statement
Funding: The research is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number R01AI124389 (PIs: FT and TB). EPIC-HIV development was supported by the Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaboration (IRC) Early-warning Sensing Systems for Infectious Diseases (i-sense) EP/K031953/1 and MRC MR/P024378/1. FT and TB are supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (Award # R01-HD084233), and FT is additionally supported by the National Institute of Mental Health (NIMH) (Award # R01MH131480). NM is a recipient of an NIHR Research Professorship award (RP-2017-08-ST2-008). The Africa Health Research Institute's HDSS is funded by the Wellcome Trust (201433/A/16/A), and the South Africa Population Research Infrastructure Network (funded by the South African Department of Science and Technology and hosted by the South African Medical Research Council). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding bodies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols for the AHRI's population-based HIV testing platform and HITS intervention were approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (BE290/16 and BFC398/16). Permission for the trial was obtained from the KwaZulu-Natal Department of Health, South Africa. Participation in the HIV surveillance and HITS trial is completely voluntary. Individuals may choose not to answer and/or participate in any component of the HIV surveillance and to withdraw at any time. Written informed consent was sought from individuals aged ≥ 18 years, and parental or guardian consent with child assent for individuals of 15-17 years old were obtained.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests
The authors declare no conflicts of interest.
Data Availability
The de-identified datasets are available upon reasonable request through the Africa Health Research Institute (AHRI) data repository at https://data.ahri.org/index.php/home
